150 related articles for article (PubMed ID: 36146745)
1. Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments.
Yu S; Wei Y; Liang H; Ji W; Chang Z; Xie S; Wang Y; Li W; Liu Y; Wu H; Li J; Wang H; Yang X
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146745
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
[TBL] [Abstract][Full Text] [Related]
3. Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.
Kordyukova LV; Moiseenko AV; Serebryakova MV; Shuklina MA; Sergeeva MV; Lioznov DA; Shanko AV
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851694
[TBL] [Abstract][Full Text] [Related]
4. Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model.
de Castro Barbosa E; de Souza Andrade A; Duarte MM; Faria G; de Melo Iani FC; Ataide ACZ; Cunha LM; Duarte CG; Fialho SL; Caldas S
Mol Immunol; 2022 Jul; 147():199-208. PubMed ID: 35644072
[TBL] [Abstract][Full Text] [Related]
5. β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V; Prajeeth CK; Jendrny P; Twele F; Meller S; Pink I; Fathi A; Addo MM; Volk HA; Osterhaus A; von Köckritz-Blickwede M; Schulz C
J Virol Methods; 2023 Jul; 317():114733. PubMed ID: 37068591
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.
Kulkarni R; Patil HP; Palkar S; Lalwani S; Mishra AC; Arankalle V
J Virol Methods; 2021 Jan; 287():113996. PubMed ID: 33126149
[TBL] [Abstract][Full Text] [Related]
7. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
[TBL] [Abstract][Full Text] [Related]
8. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of β-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles.
Bagrov DV; Glukhov GS; Moiseenko AV; Karlova MG; Litvinov DS; Zaitsev PА; Kozlovskaya LI; Shishova AA; Kovpak AA; Ivin YY; Piniaeva AN; Oksanich AS; Volok VP; Osolodkin DI; Ishmukhametov AA; Egorov AM; Shaitan KV; Kirpichnikov MP; Sokolova OS
Microsc Res Tech; 2022 Feb; 85(2):562-569. PubMed ID: 34498784
[TBL] [Abstract][Full Text] [Related]
10. The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET.
Liu C; Mendonça L; Yang Y; Gao Y; Shen C; Liu J; Ni T; Ju B; Liu C; Tang X; Wei J; Ma X; Zhu Y; Liu W; Xu S; Liu Y; Yuan J; Wu J; Liu Z; Zhang Z; Liu L; Wang P; Zhang P
Structure; 2020 Nov; 28(11):1218-1224.e4. PubMed ID: 33058760
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Propagation, Inactivation, and Safety Testing of SARS-CoV-2.
Jureka AS; Silvas JA; Basler CF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32517266
[TBL] [Abstract][Full Text] [Related]
14. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
[TBL] [Abstract][Full Text] [Related]
15. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
16. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
17. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
[TBL] [Abstract][Full Text] [Related]
18. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
19. Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production.
Herrera-Rodriguez J; Signorazzi A; Holtrop M; de Vries-Idema J; Huckriede A
Vaccine; 2019 Mar; 37(12):1630-1637. PubMed ID: 30765167
[TBL] [Abstract][Full Text] [Related]
20. Inactivated infectious haematopoietic necrosis virus (IHNV) vaccines.
Anderson E; Clouthier S; Shewmaker W; Weighall A; LaPatra S
J Fish Dis; 2008 Oct; 31(10):729-45. PubMed ID: 18752542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
